Fuisz Pharma LLC Announces Allowance of Patent Claims by the Israeli Patent Office Relating to the Programming of Bodily Fluid Analyzers

News provided by

Fuisz Pharma LLC

15 Oct, 2013, 08:00 ET

MIAMI, Oct. 15, 2013 /PRNewswire/ -- Fuisz Pharma LLC today announced today that the Israeli Patent Office has allowed claims in a patent case that parallels US 7,824,612 ("Bodily fluid analyzer, and system including same and method for programming same").

Richard C. Fuisz, M.D., commented:  ""The allowance of parallel claims in Israel underscores the novelty of the '612 art, which enables a physician to set patient specific analyte threshold values, programming these physician set values onto a bodily fluid analyzer, and generating alert levels from a bodily fluid analyzer.

This allowance is an important addition to our current portfolio of diagnostic art, which includes the '612, a recent allowance in Japan based on the '612, and two separate pending US applications.   One of these pending US applications deals with the consolidation, interpretation and presentation of data from bodily fluid analyzers.  That means doctor friendly data.   We cannot substitute algorithmic-driven server based conclusions for the doctor's art.  The second US application is a novel system directed to the promising field of breath-based diagnostics that recently published as US 20130239647 A1 ("Method and System to Amplify and Measure Breath Analytes")."

Dr. Richard Fuisz is founding member of Fuisz Pharma LLC (http://en.wikipedia.org/wiki/Richard_Fuisz).

Joseph Fuisz, Managing Member of Fuisz Pharma LLC, stated:   "The '612 patent has been subject to litigation brought by plaintiffs Elizabeth Holmes and Theranos (www.theranos.com) in the United States District Court for Northern California (5:11-cv-05236-PSG).  A related action brought by Elizabeth Holmes and Theranos against a separate defendant in DC Superior Court was dismissed by Judge Craig Iscoe (2012 CA 009617 M).   Fuisz Pharma LLC is confident it will prevail on the merits including on certain bases analogous to those cited by Judge Iscoe in his dismissal Order."

Fuisz Pharma LLC is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.  Fuisz Pharma is also active in diagnostic systems.  Fuisz Pharma has its headquarters in Miami. www.fuisz.com.

SOURCE Fuisz Pharma LLC

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.